SDCBP and cancer: Lysyl‐tRNA synthetase (KRS) is released from cancer cells to modulate the inflammatory response, with caspase‐8 cleavage of KRS exposing the KRS PDZ syntenin‐binding domain, enhancing its EV‐loading.